Live News EQUITY L impact Jun 30, 2026, 03:33 PM UTC

RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Raises Price Target to $51

RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ: NAMS ) with a Outperform and raises the price target from $47 to $51.

SQUAWKNEWS Updated Jun 30, 2026, 03:33 PM UTC

RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ: NAMS ) with a Outperform and raises the price target from $47 to $51.